

May 20, 2024

Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai - 400 051

Listing Department
BSE Limited
25th Floor, Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

Sub: Corporate Presentation Q4 & FY24

Dear Sir / Ma'am

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations), please find attached herewith Corporate Presentation of the Company for Q4 & FY24, which the Company proposes to share with analysts/ investors.

We request you to kindly take the same on your records.

Thanking you,
Yours Faithfully,

For Dr. Lal PathLabs Limited

Vinay Gujral
Company Secretary and Compliance Officer

Encl.: As above



Dr Lal PathLabs Limited (DLPL)

Corporate Presentation

May 2024

Celebrating 75 Years of
"Enabling Healthier Lives"



Disclaimer

By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations:

The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the "Company") for use in presentations by the Company at analyst and investor meetings and does not constitute a recommendation regarding the securities of the Company. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither the Company nor any of its advisors or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially. Neither the Company nor any of its advisors or representatives is under any obligation to update or keep current the information contained herein. The information communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will", "expects" and "anticipates" and words of similar import. By their nature forward looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Any investment in securities issued by the Company will also involve certain risks. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, readers should not unduly rely on these forward looking statements. The Company, its advisors and representatives assume no responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus under the (Indian) Companies Act, 2013 and will not be registered with any registrar of companies. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy securities for sale in the India. This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered, sold or delivered within the United States or to U.S. persons absent from registration under or an applicable exemption from the registration requirements of the United States securities laws. This presentation and the information contained herein is being furnished to you solely for your information and may not be reproduced or redistributed to any other person, in whole or in part. In particular, neither the information contained in this presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the U.S., Canada, Australia, Japan or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of the United States or other national securities laws. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will not be accepted.

By reviewing this presentation, you are deemed to have represented and agreed that you and any person you represent are either (a) a qualified institutional buyer (within the meaning of Regulation 144A under the Securities Act) or (b) not a U.S. person (as defined in Regulation S under the Securities Act) and are outside of the United States and not acting for the account or benefit of a U.S. person.

Company Overview

4

Investment Highlights

16

Financial & Operating Highlights

21

DLPL Strategy for Future Growth

30

DISCLAIMER: This presentation may contain 'forward-looking' statements at places. The Company's business operations remain subject to undetermined contingencies and risks. Dr. Lal PathLabs Limited would not be liable for any action undertaken based on such 'forward-looking' statements and does not commit to revising/updating them publicly.



Corporate Overview

WIDENING
HORIZONS
SERVING
BETTER



Dr. Lal PathLabs – At a Glance

12%

3 Year Revenue
CAGR

35%

ROCE
Excl. Cash &
Investments

240%

Equity Dividend for
FY23-24

4,857[#]


Pathology &
Radiology tests;
Comprehensive Test
menu

280

Labs; Geographically
spread-out network

5,762

Patient Service
Centers (PSC's)



As on March 31, 2024

*Largest on the basis of revenue and presence

[#] Test count has been rationalized basis current practice

Overview of Dr Lal PathLabs

Most trusted healthcare brand in diagnostic services

Catalogue of **343** test panels, **3,075** pathology tests and **1,439** radiology and cardiology tests¹

Collected and processed **~78.2** mn samples from **~27.6** mn patients in FY24; **~72.3** mn samples from **~26.9** mn patients in FY23

FY24: Revenue: **INR 2,226.6 Cr.**; EBITDA: **INR 609.0 Cr** (Margin: **27.4%**); PAT: **INR 362.3 Cr** (Margin: **16.3%**);
FY23: Revenue: **INR 2,016.9 Cr.**; EBITDA: **INR 490.0 Cr** (Margin: **24.3%**); PAT: **INR 241.1 Cr** (Margin: **12%**);

Pan-India integrated coverage with **280** clinical labs (including National Reference Lab at Delhi and Regional Ref Lab at Kolkata, Bangalore & Mumbai), **5,762** Patient Service Centers (PSCs) and **11,619** Pick-up Points (PUPs)¹

Customers include individuals, corporates and institutions, healthcare service providers as well as hospital and clinical labs (lab management)

1. As on March 31, 2024.

Test Menu

Routine testing

- Bio-chemistry
- Hematology
- Clinical pathology
- Microbiology
- Basic radiology



Specialized testing

- Molecular diagnostics
- Flowcytometry
- Genetics / Cytogenetics / Genomics
- Histopathology/Immunohistochemistry and Digital Pathology and AI



- Proteomics
- Next Generation Sequencing
- Renal Pathology and TEM (Transmission Electron Microscopy)
- Transplant Immunology



Accreditations



ISO15189:2012/2022
ISO9001:2015
ISO27001:2013

1949 – 2005

Foundation

- **1949:** Founded by Dr. Major S. K. Lal
- **1995:** Company incorporated as Dr. Lal PathLabs Private Ltd.
- **2000:** Three clinical labs receive NABL¹ accreditation
- **2001:** Received ISO 9001:2008 certification
- **2002:** Received 'International Accreditation' from CAP²

2005 – 2010

Building capabilities for scale up

- **2005:** onwards: Investment by WestBridge Capital
- **2008:** Acquisition of Paliwal Medicare Private Limited and Paliwal Diagnostics Private Limited
- **2010:** National Reference Lab set up in Delhi

2010 – 2015

Strong position in North India, building network in other geographies

- Investment by TA Associates
- Clinical laboratories expansion in North region
- Growing the business in East region
- Entry into the South and West regions
- Multiple acquisitions to scale network
- Successful IPO listing in Dec 2015

2015 -2020

Higher contribution from Rest of India, Commissioned state of the art Kolkata Reference Lab

- Higher contribution from Rest of India business & focus on bundled test program "Swasthfit"
- Successful commissioning of Regional Reference Lab at Kolkata in 2018
- Inorganic growth through acquisition of laboratories in Western & Southern India


2020 onwards

Pan India Player – Acquired Suburban, Building South Ecosystem

- First to set-up RT-PCR testing network in 2020
- Completed acquisition of Suburban Diagnostics in 2021
- Expanded South ecosystem through Bengaluru Reference Lab and network of Hub & Satellite labs
- Established hub labs in North region
- Spearheading investments in Digital and InfoSec
- Successful commissioning of Regional Reference Lab at Mumbai in 2023


1. NABL: National Accreditation Board for Calibration and Testing Laboratories.
2. CAP: College of American Pathologists.

Most trusted healthcare brand in Diagnostic Services




Pillar of a Strong Brand

- Accreditations from CAP, NABL and ISO
- Centrally administered surveillance programs
- Coverage in metros, Tier 1, Tier 2 & Tier 3+ cities
- Wide reach through PSCs and PUPs
- 24x7 access including online access and home collection
- Dedicated logistics team



Collection network

LPL's scalable business model provides strategic advantage for expansion and consolidation




Single brand pulls patients

Walk-in customers account for highest share of revenues

Diverse, large customer pool offers monetization opportunities

Digital Touchpoints across patient journey



Experienced Management team



(Hony.) Brig. Dr. Arvind Lal
Executive Chairman



Dr. Om Manchanda
Managing Director



Dr. Vandana Lal
Whole-time Director



Shankha Banerjee
Chief Executive Officer-
Designate



Ved Prakash Goel
Group Chief Financial Officer



Munender Soperna
Chief Information Officer




Jai Prakash Meena
Chief Operating Officer



Manoj Garg
Group Chief Human
Resources Officer

Key ESG Initiatives



Savings of >1.3 million aliquots and >5210 tons of plastic waste in our lab – a strong commitment to sustainability

Dr. Lal Pathlabs' leadership vision focuses on continuous improvement while maintaining best-in-class patient services. Furthermore, we are strongly committed to optimizing our laboratory's environmental footprint.

We **reduced the need for aliquots by 93%** by replacing our previous system configuration^{1,2} with new, innovative automation, analyzers, and IT solutions. Reduced use of plastic for aliquots optimizes **waste management** and **significantly reduces CO² emissions**.

>1.3 millions



aliquots eliminated per year²

>5210 tons

of plastic waste eliminated³

>INR 435 millions

saved in aliquot creation cost^{2,5}



>21,571 tons of CO₂ emissions

eliminated every year⁴

Equivalent to carbon sequestered by

3231 tree seedlings

grown for 1 year⁴



Protecting resources



Reducing the carbon footprint



Saving energy required for aliquot creation



Combating climate change



Supporting return on investment

1. Siemens Healthineers automation and IT solution vs. the previous system configuration from Roche Diagnostics, Abbott Diagnostics, and Beckman Coulter Diagnostics.

2. Case study: Dr. Lal Pathlabs harnesses the power of digitalization. Published by Siemens Healthcare Diagnostics Inc. - Order No. 30-22-DX-1342-76 - 08-2022 - © Siemens Healthcare Diagnostics Inc., 2022.

3. ZWE_Policy-briefing_The-impact-of-Waste-to-Energy-incineration-on-Climate.pdf

4. Theoretical worldwide average using the [epa.gov/energy/greenhouse-gases-equivalencies-calculator](https://www.epa.gov/energy/greenhouse-gases-equivalencies-calculator)

5. Expected financial savings for the contract duration, depending on test mix and market pricing during this time period.

Key Awards & Recognition



Top 100 Global Most Loved Workplace 2023



Gold Award
QCI – D. L. Shah Quality Awards - 2022



Business Standard Star SME of the year 2022



Best Brands Healthcare 2022



GAPIO Excellence in Diagnostics Award 2022



Diagnostic Chain of the Year – West
Awarded by the prestigious Healthcare Awards, from The Economic Times in 2022



CSR Award 2022



ICICI Lombard & CNBC TV18 India Risk Management Awards 2022 – Healthcare



CFO100 Roll of Honour 2022



Financial Express CFO of the year 2022



Dr. Om Manchanda honoured and awarded as 'Healthcare Personality of the Year, 2020' by FICCI



EY Entrepreneur of The Year 2019 – Life Sciences & Healthcare



Data Quest Technology Award 2015 – Excellence in Implementation of Technology



VC Circle Healthcare Summit 2013 – Best Diagnostic Company



Computerworld Honors Laureate Program, 2012



Frost and Sullivan 4th Annual India Healthcare Excellence Award, 'Diagnostic Service Provider Company of the Year 2012'



Franchise India Excellence Award in Hall of Fame Category (2011, 2012)




Franchisor of the Year (Healthcare) - Franchise Plus Awards 2010



Padma Shri – (Hony) Brig. Dr. Arvind Lal (2009)

Investment Highlights



Indian Healthcare Services is a large and growing opportunity

~1.51 bn

India's expected population in 2030¹

Rs. 16.5-17.5 trillion

Expected India's healthcare industry size in FY 28²

\$10.76 bn

Close to Rs. 89,155 crore was allocated to the Ministry of Health and Family Welfare, under Union Budget 2023-24⁶

2.5%

Government Expenditure on healthcare (as % of GDP) in FY25⁵


~50.6%

Out of pocket expenses to overall healthcare spends³

\$6.8 bn

The amount that Indian Government is planning to introduce as a credit incentive program (Rs. 500 bn) to boost the country's healthcare infrastructure⁶

Per capita current expenditure on health in \$ terms (2020)⁴




India, highly underpenetrated market

Globally: Total Healthcare Expenditure is 10.9% of GDP


Source: (1) UN Department of Economic and Social Affairs, World Population Prospects 2022, CRISIL MI&A, (2) Industry, CRISIL MI&A (3) Global Health Expenditure Database accessed in March 2023, CRISIL MI&A (4) Global Health Expenditure Database – World Health Organisation in March 2023, CRISIL MI&A (5) Article by Outlook India, (6) IBEF

Diagnostic Services Industry Size




Screening, early detection, and monitoring reduce downstream costs

Growth Drivers




Source: Industry Data, Centrum Institutional Research Report, Axis Capital Report, ICICI Securities Report

Diagnostic Services industry continues to remain highly fragmented



Largely fragmented and unorganized

Region wise Revenue



Diagnostic penetration in rural market is lower, while the opportunity size remains big



Financial & Operating Highlights

WIDENING
HORIZONS
SERVING
BETTER



Q4 FY24 Performance Overview

	Q4 FY24		Q4 FY23
↑ 11.1%	Rs. 545 crore	Revenue	Rs. 491 crore
↑ 25.1%	Rs. 145 crore	EBITDA	Rs. 116 crore
↑ 50.8%	Rs. 86 crore	PAT	Rs. 57 crore
↑ +2%	24%	SwasthFit Contribution	22%
↑ +3 Cr.	Rs. 112 crore	Cash Generated	Rs. 109 crore

Financials


Particulars (Rs. Cr.)	Q4 FY24	Q4 FY23	Gr %	FY'24	FY'23	Gr %
Revenue	545	491	11.1%	2,227	2,017	10.4%
Operating Expenditure	401	375		1,617	1,527	
EBITDA	145	116	25.1%	609	490	24.4%
<i>Margins</i>	<i>26.5%</i>	<i>23.6%</i>		<i>27.4%</i>	<i>24.3%</i>	
Other Income	18	14		69	42	
Depreciation	37	38		144	150	
EBIT	126	92	37.0%	535	381	40.2%
<i>Margins</i>	<i>23.2%</i>	<i>18.8%</i>		<i>24.0%</i>	<i>18.9%</i>	
Finance Cost	7	9		29	38	
PBT	120	83	44.1%	505	344	47.0%
<i>Margins</i>	<i>22.0%</i>	<i>16.9%</i>		<i>22.7%</i>	<i>17.0%</i>	
PAT	86	57	50.8%	362	241	50.3%
<i>Margins</i>	<i>15.7%</i>	<i>11.6%</i>		<i>16.3%</i>	<i>12.0%</i>	
EPS (Basic)	10.1	6.8		43.0	28.8	

Consolidated Balance Sheet


Assets (Rs. Cr.)	Mar-24	Mar-23	Equity and liabilities (Rs. Cr.)	Mar-24	Mar-23
Non-current assets			Equity		
Property, plant and equipment	199	200	Equity share capital	83	83
Capital work-in-progress	4	3	Other equity	1766	1583
Right-of-use assets	144	201	Non-controlling interests	36	33
Investment in Property	34		Total equity	1,885	1,699
Goodwill	548	548			
Other intangible assets	303	356	Non-current liabilities		
Intangible assets under development	2	2	Financial liabilities		
Financial assets			(i) Borrowings	0	84
(i) Other financial assets	31	40	(ii) Lease liabilities	103	130
Non-current tax assets (net)	17	21	Deferred tax liabilities (net)	2	3
Deferred tax assets (net)	45	40	Total non-current liabilities	105	217
Other non-current assets	2	1			
Total non-current assets	1,329	1,412	Current liabilities		
			Financial liabilities		
Current assets			(i) Borrowings	83	153
Inventories	37	34	(ii) Lease liabilities	61	53
Financial assets			(iii) Trade payables	187	156
(i) Investments	114	150	(iv) Other financial liabilities	49	46
(ii) Trade receivables	78	71	Provisions	38	29
(iii) Cash and cash equivalents	361	264	Current tax liabilities (net)	13	1
(iv) Bank balances other than (iii) above	469	402	Other current liabilities	35	32
(v) Loans	1	1	Total current liabilities	466	470
(vi) Other financial assets	47	36	Total Equity and liabilities	2456	2,386
Other current assets	20	16			
Total current assets	1,127	974			
Total assets	2,456	2,386			

Operating Highlights


No. of Clinical Laboratories




No. of PSCs




No. of PUPs



No. of Patients (Mn)





No. of Samples (Mn)



Robust financial performance


Covid & Non Covid Revenue

(INR Cr.)



EBITDA, PAT and Return on Net Worth

(INR Cr.%)




EBITDA Margin	26.9%	24.3%	27.4%
PAT Margin	16.8%	12.0%	16.3%
ROCE	26.2%	24.3%	34.8%

- Growth driven primarily by increasing patient volumes and realization
- Increase in operating margin due to economies of scale and cost efficiencies


Note: Results includes Suburban financials wef 12th Nov'21

Robust financial performance (Cont'd)

Fixed Asset Turnover¹ Times



Cash and Cash Equivalents (INR Cr.)



- Self funded growth on account of strong cash flow generation
- Attractive fixed asset turnover ratio given asset-light model
- Current net cash position and internal accruals expected to fund next phase of growth

1. Fixed Asset Turnover = Total Revenue / Net PP&E as per Ind AS

Management Commentary

Commenting on the performance, (Hony) Brig. Dr. Arvind Lal, Executive Chairman said:

“Dr. Lal PathLabs remains dedicated to driving sustainable growth in response to the demand for dependable diagnostic services. We’re investing in an efficient, technology-enabled network to accommodate the growing volume of samples and enhance patient accessibility.

Our strategic focus areas, including geographical expansion, portfolio diversification and digital transformation, are driving significant progress. By leveraging our unique strengths, such as DLPL and Suburban’s distinct USPs, we’re prioritizing network synergies as well as employing a phygital mechanism to meet evolving consumer preferences.

As we navigate through competitive landscape and pursue growth opportunities, our approach emphasizes on both organic and inorganic opportunities, particularly in the untapped markets. Through continuous innovation, branding efforts and prudent financial management, we’re dedicated to maintaining our leadership position and enhancing shareholder value.”



(Hony) Brig. Dr. Arvind Lal,
Executive Chairman

Commenting on the performance, Dr. Om Manchanda, Managing Director said:

“A strategic thrust towards widening and deepening our geographical footprint, thereby, delivering sustainable volume and value growth continues to guide us. Initiatives are underway to gain traction in both B2C and B2B segments. Another peg in this approach is the development of medical centers of excellence, whereupon we focus on positive patient outcomes for identified underlying conditions through accurate and timely diagnosis.

Expanding further into Mumbai, and select parts of Maharashtra via Suburban, together with development of presence in tier 3 and 4 towns remains a fundamental goal. To strengthen Suburban’s operations, we’re focusing on sampling promotion and brand building and expect to see traction in the coming months. Additionally, under the DLPL brand, we are developing new lab towns to expand our reach. As the leading brand, we are setting the tone of growth and profitability, with focused actions driven by an experienced team.”



Dr. Om Manchanda,
Managing Director

Commenting on the performance, Mr. Shankha Banerjee, Chief Executive Officer-Designate said:

“We are thrilled to have concluded the year on a strong note, achieving 10.4% growth in Revenue and 50.3% growth in PAT . In FY24, we provided services to 27.6 million patients and tested a total of 78.2 million samples, representing a growth of 8.1% in samples over previous year.

We’re expanding our reach in core markets by strengthening our presence in Tier 3 and Tier 4 towns. Simultaneously, we’re intensifying efforts in key clusters of Western and Southern India.

We continue to leverage our digital infrastructure, including advanced AI and data analytics, to enhance patient experience and deliver operational excellence.

We have taken a lead in bundling routine tests under 'Swasthfit' and have been successful thus far. We will continue to expand its reach and develop programs for sustain growth trajectory.”




Mr. Shankha Banerjee,
Chief Executive Officer -Designate

Vision, Mission & Values

Be the most trusted healthcare partner, enabling healthier lives

To be an undisputed market leader by providing accessible, affordable, timely and quality healthcare, diagnostics, applying insights and cutting-edge technology to create value for all stakeholders



Customer First

Ethics & Integrity

Quality

Accountability

Empathy & Compassion

DLPL Strategy for future growth

Significantly leverage the strong digital infrastructure

- Deployed AI, data analytics, machine learning tools to elevate the patient experience & offer customized solutions
- Dedicated digital team in place to amplify the volume trajectory

Enhance high-end test portfolio of super-specialty & bundled test


- Created specialty verticals like Genevolve to focus on genomics, L-CoRD to focus on reproductive diagnostics, and L-ACE to focus on auto-immune disorders.
- 'Swasthfit' remains at the core, to offer comprehensive bundled solutions to patients

Maintain leadership position in the existing core markets

- Leverage strong brand equity in core markets of North India including Delhi NCR
- Offer value to patients by up-selling opportunities

Drive higher volumes in high-potential markets of Western & Southern India

- Follow cluster city approach to steer growth in key pockets
- Enhance presence in Maharashtra especially Mumbai through Suburban Diagnostics
- Launched Reference labs in Bengaluru & Mumbai



Leveraging digital infrastructure to make life easier for patient

New Website Launch

- New age user intuitive website.
- Responsive , mobile friendly web designs.
- SEO friendly for improved customer reach
- Strategic placement of Buttons and Web forms to generate more leads and better order conversion rates from website

Reco.ai

- LPL's own AI based Recommendation Engine
- Recommends Patient relevant tests as per his current health condition, past report trends, demographic details, etc.

Logistics App

- Machine Learning based FE Route Generation
- Machine Learning based Tube Scanning Bag creation process.
- Secure QR Code based handshake for every process.
- Geo-fencing and Precious sample recognition Intra and Intercity sample movement.



Wallet

- Senior Citizen Wallet: Wallet points on every booking for Senior Citizen Patients.
- Phlebo Wallet: Wallet points on enhanced superior services to customers.

One Registration

- One unified platform for all POS registrations
- Error Proofing

Chatbot 2.0

- New version of Chatbot.
- Book an appointment functionality.
- ETR and Report visibility of customer orders. Recommendation of Preventive Health Checkups

Technical Lab Operations



Only lab in India to introduce the **Donor derived cell free DNA (LIQUID BIOPSY) technique** for monitoring in cardiac, lung and renal transplant patients.



First lab to introduce the **ONCOPRO TSO500 Comprehensive Genomic Profiling- 500 genes panel**



LACE and the centre of excellence in Reproductive medicine – **LCORD**



Relaunched the Lipid panels incorporating the latest guidelines and the SCVD risk profiling for patients



First lab in India to use **AI as an adjunct reporting for prostate cancer and breast cancer reporting** – enhancing the accuracy of pertinent parameters for reporting which affect the therapy guidelines for patients (Gleason grading and perineural invasion)




Launched **COE in Autoimmunity** – Unparalleled test menu in autoimmune diseases in India



Only private lab to have **two electron microscopes – TEM** (Transmission Electron Microscopy) for clinical diagnostics.



New Research paper published entitled **“Emergence of Multidrug Resistant Enterococcus Species Isolated from Clinical Samples in North India”** in international journal Global Journal of Microbiology Research(GJMR).



Successful completion of 3 years of Launch

Wide Test offering with 160+ New Tests

Wellness Genomics & Pharmacogenomics are upcoming segment

Direct reach of 3000+ Doctors

Dedicated Business Development team for Genetic Tests

State of art technologies In-House at 4 Reference Labs

Highest Quality Standards in the Industry

Best in the Industry CAP Proficiency Testing Score at 96% for National Reference Lab

Consistently high EQAS Performance Testing Score at 97.3% for Satellite Labs

CAP accreditation 2 labs, NABL accreditation 36 Labs

Real time quality control monitoring


Risk based quality assurance framework

100+ Quality improvement meetings on a daily basis with the network partners

Digitally enabled solutions implemented for quality audits and trainings



Patent has been granted to Dr. Lal PathLabs for an invention related to REAL TIME QUALITY CONTROL MONITORING for the period of 20 years



Enhanced Customer Experience in Home Collection



Control Tower Implementation

“Control Tower” implementation provides a complete visibility of Patient samples across the sample processing lifecycle. The insights will help the business users to reduce delay and improve processing leading to better customer service.

Control Tower Teams



Front Desk

Failure Indicator Areas - Home Collection, Credit management & Sample/Registration Deficiency



Logistics

Failure Indicator Areas - Unregistered Samples, Bagging & Shipping of samples



Lab Operations

Failure Indicator Areas - samples scan-in & scan-out, Shipment creation, Report Validation



Digital

Failure Indicator Areas: Delay in report upload and payment

Key Highlights

- Centralized Monitoring Team for “Control Tower” Operation
- Real-time information for the delays happening across sample processing lifecycle with actionable insights
- Quick decision making
- Drill-down level information available till last leaf i.e. Lab Number / Field Executive
- Information accessible based on Roles & Rights
- Overall design is based on “Mobile First” Approach

D365 Cloud Data Lake

- Future ready Cloud architecture with easily scalable and upgradable
- Cloud ERP Microsoft Dynamics 365 for Finance & Operations
- Data for “Control Tower” is processed through “Data Lake” hosted on Cloud
- “Data Lake” helps in consolidating the data from multiple source systems and provides easy access information securely

Data Loss Prevention

- State-of-the-art data loss prevention technology to monitor and prevent the disclosure of information
- Data classification platform for information labeling and handling according to severity of data
- Rights management system to enable persistent data-centric protection



- Deployed next generation cyber technologies such as CASB (Cloud Access Security Broker), EDR (Endpoint Detection & Response), ATP (Advance Threat Protection), File Sandboxing, Email Zero-Day Protection, Risk-Based Conditional access to prevent the new-age cyberattacks

Extended Detection and Response

Software Security

- Vulnerability Assessment & Penetration Testing of IT apps and systems including cloud infra
- Periodic secure code and configuration reviews of mission-critical systems



- Security operations center to monitor cyber threats 24x7
- Cyber Crisis Management Plan - Readiness, Response & Recovery to achieve the cyber resiliency


Security Operations Center

Threat Intelligence

- Threat intel platform to monitor the surface, deep and dark web for credential disclosures, data leaks, frauds, scams, etc
- Proactive detection and mitigation of vulnerabilities of publically exposed systems



Shareholding as of 31st March, 2024



*Mutual Funds includes Alternate Investment Funds as well

Contact Us

About Dr. Lal PathLabs Limited (DLPL)

Dr. Lal PathLabs Limited is one of India's leading consumer healthcare brand in diagnostic services.

It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. The catalogue of services includes 343 test panels, 3,075 pathology tests and 1,439 radiology and cardiology tests as on March 31, 2024.

As on March 31, 2024, DLPL's has 280 clinical labs (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata, Bangalore & Mumbai), 5,762 Patient Service Centers (PSCs) and 11,619 Pick-up Points (PUPs). In FY23 & FY24, DLPL collected and processed approximately 72 million samples and 78 million samples from 26.9 million and 27.6 million patients, respectively.

Additional information on Dr. Lal PathLabs Limited: Corporate Identification No: L74899DL1995PLC065388

Website: <https://www.lalpathlabs.com>

**For further
information
please contact:**

Ved Goel

Dr. Lal PathLabs Limited

Tel: +91 124 301 6500

Fax: +91 124 423 4468

E-mail: ved.goel@lalpathlabs.com

Siddharth Rangnekar / Nishid Solanki

CDR India

Tel: +91 22 66451209 / 1221

Fax: +91 22 66451213

Email: siddharth@cdr-india.com / nishid@cdr-india.com



Thank you

Celebrating 75 Years of
"Enabling Healthier Lives"

We **THANK YOU** for being part of our Journey.



 Dr Lal PathLabs